KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis.

Marta Simone, Roberto Palumbi, Mariaclara Achille, Stefania Micella, Mara Pascali, Antonia Peschechera, Alessandra Gabellone, Lucia Marzulli, Andrea De Giacomo, Giulia Maggi, Giorgio Reggiardo, Mariagrazia Felisi, Rosa Padula, Donato Bonifazi, Massimiliano Valeriani, Laura Papetti, Roberta Lanzillo, Valentina Torri Clerici, Lucia Margari

Neurol Sci 46(10) 5391-5400

PMID40775552
PMCIDPMC12488838
DOI10.1007/s10072-025-08377-3
发表日期2025-08-08
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Paediatric-onset Multiple Sclerosis (POMS) is a rare, highly active disease requiring timely disease-modifying therapy. OBJECTIVES: This trial compared the efficacy and safety of intramuscular (i.m.) Interferon beta-1a (IFN-beta 1a) and subcutaneous (s.c.) Glatiramer Acetate (GA). METHODS: A 96-week, Phase IIIb, multicenter, open-label randomized trial enrolled 30 participants (ages 12-17). Patients were randomized into two groups: 15 received i.m. IFN-beta 1a, and 15 received s.c. GA. The primary endpoint was MRI disease activity-free status; secondary outcomes included annualized relapse rate (ARR), time to first relapse, Expanded Disability Status Scale (EDSS), cognitive and fatigue scores, and quality of life. RESULTS: The groups differed by age but not sex. MRI disease activity-free status did not differ (p = 0.09). ARR was significantly lower in the GA group (0.20; 95% CI 0.08-0.42) than in the IFN-beta 1a group (0.57; 95% CI 0.31-0.95, p = 0.02). EDSS, cognitive, fatigue, and quality-of-life scores were comparable. Notably, 50% of GA patients and 30% of IFN-beta 1a patients switched to higher efficacy treatments. CONCLUSIONS: Both treatments showed similar efficacy and safety, but early high-efficacy therapy may be preferable for POMS management. TRIAL REGISTRATION: EudraCT Number: 2017-005129-18. https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-005129-18/IT.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 3

Fig. 3 Time to first relapse, assessed through Kaplan–Meier curves

Time_to_first_relapse

Time to first relapse

Fig. 3 · Panel Time_to_first_relapse

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Time_to_first_relapse 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:flat topline artifact
查看结果
KM Figure1 个面板

Fig. 4

Fig. 4 Cumulative survival function (event = treatment switch)

Cumulative_survival_function_event_treatment_switch_

treatment switch

Fig. 4 · Panel Cumulative_survival_function_event_treatment_switch_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Cumulative_survival_function_event_treatment_switch_ 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Participant flow diagram
非 KM Figure
Fig. 2Fig. 2 Proportion of patients free of new or newly enlarging T2 hyperintense on brain MRI scans at 96 weeks
非 KM Figure